Hu23F2G Anti-Adhesion to Limit Cytotoxic Injury Following AMI - HALT-MI

Description:

HALT-MI was a multicenter, randomized double-blinded trial to evaluate the safety and efficacy of Hu23F2G (an antibody directed against the leukocyte CD11/CD18 integrin receptor) in reducing infarct size in patients with ST-segment elevation acute myocardial infarction (STEMI) undergoing primary angioplasty.